Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced it will host a live webinar titled "Inside MEAI: New Insights from the CMND-100 Psychedelic Clinical Trial" on Wednesday, June 10, 2026, from 4:00 PM to 5:00 PM IDT.

Interested participants are invited to register and secure their spot in this exclusive session.

The webinar will provide an in-depth review of the latest clinical data from the Company's ongoing FDA-approved Phase I/IIa multi-center trial evaluating CMND-100, its proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).

The webinar will feature presentations and discussions by leading clinical investigators from the CMND-100 multi-center trial. Dr. Anahita Bassir Nia, MD, an addiction psychiatrist and Assistant Professor of Psychiatry at the Yale School of Medicine, will share insights from the Yale trial site. Her research focuses on developing novel treatments for addiction and stress-related disorders, with a particular emphasis on cannabinoids and psychedelics. She leads clinical trials examining the therapeutic potential of psychedelics and other novel compounds for alcohol use disorder, depression, and PTSD, while conducting mechanistic studies using advanced brain imaging to explore neuroplasticity, functional connectivity, and endocannabinoid system dysregulation in addiction and trauma-related conditions.

Joining her will be Dr. Jennifer Ellis, Ph.D., Assistant Professor and licensed clinical psychologist at Johns Hopkins Medicine, who serves as a principal investigator at the Johns Hopkins trial site. Dr. Ellis's research centers on identifying new therapeutics for substance use disorders and optimizing treatment outcomes for individuals with co-occurring psychiatric conditions.

Dr. Adi Zuloff-Shani, Ph.D., Chief Executive Officer of Clearmind Medicine, who will moderate the session and provide an overview of the clinical development strategy and corporate updates, said: "The positive safety data and encouraging signals we have seen, together with the expertise of our distinguished clinical investigators, reinforce our belief in MEAI's potential as a transformative, non-hallucinogenic treatment option for Alcohol Use Disorder."